Development and validation of a risk prediction model of preterm birth for women with preterm labour symptoms (the QUIDS study):A prospective cohort study and individual participant data meta-analysis by Stock, Sarah J et al.
                          Stock, S. J., Horne, M., Bruijn, M., White, H., Boyd, K. A., Heggie, R.,
Wotherspoon, L., Aucott, L., Morris, R. K., Dorling, J., Jackson, L.,
Chandiramani, M., David, A. L., Khalil, A., Shennan, A., van Baaren,
G-J., Hodgetts-Morton, V., Lavender, T., Schuit, E., ... Norrie, J.
(2021). Development and validation of a risk prediction model of
preterm birth for women with preterm labour symptoms (the QUIDS
study): A prospective cohort study and individual participant data
meta-analysis. PLoS Medicine, 18(7), e1003686. [e1003686].
https://doi.org/10.1371/journal.pmed.1003686
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1371/journal.pmed.1003686
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via PLoS at
10.1371/journal.pmed.1003686. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
RESEARCH ARTICLE
Development and validation of a risk
prediction model of preterm birth for women
with preterm labour symptoms (the QUIDS
study): A prospective cohort study and
individual participant data meta-analysis
Sarah J. StockID





5, Rachel K. MorrisID
6,
Jon DorlingID
7, Lesley Jackson8, Manju ChandiramaniID




12, Gert-Jan van Baaren13, Victoria Hodgetts-
MortonID
6, Tina Lavender3, Ewoud SchuitID
14, Susan Harper-Clarke15, Ben W. MolID
16,
Richard D. Riley17, Jane E. NormanID
18, John NorrieID
1
1 Usher Institute, University of Edinburgh, Edinburgh, United Kingdom, 2 MRC Centre for Reproductive
Health, Queen’s Medical Research Institute, University of Edinburgh, United Kingdom, 3 Faculty of Biology,
Medicine and Health, University of Manchester, United Kingdom, 4 Institute of Health and Wellbeing,
University of Glasgow, United Kingdom, 5 Health Services Research Unit, University of Aberdeen, United
Kingdom, 6 Institute of Applied Health Research, University of Birmingham, United Kingdom, 7 IWK Health
Centre, Halifax, Nova Scotia, Canada, 8 Queen Elizabeth Hospital, Glasgow, United Kingdom, 9 Guy’s and
St Thomas NHS Foundation Trust, London, United Kingdom, 10 Elizabeth Garrett Anderson Institute for
Women’s Health, University College London, United Kingdom, 11 Vascular Biology Research Centre,
Molecular and Clinical Sciences Research Institute, St George’s University of London, United Kingdom,
12 Department of Women and Children’s Health, School of Life Course Sciences, Kings College London,
United Kingdom, 13 Department of Obstetrics and Gynaecology, Amsterdam University Medical Center,
Amsterdam, the Netherlands, 14 Department of Epidemiology, Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, 15 Lay
Representative (no affiliation), 16 Department of Obstetrics & Gynaecology, Faculty of Medicine, Nursing and
Health Sciences, Monash University, Clayton, Australia, 17 Centre for Prognosis Research, School of





Timely interventions in women presenting with preterm labour can substantially improve
health outcomes for preterm babies. However, establishing such a diagnosis is very chal-
lenging, as signs and symptoms of preterm labour are common and can be nonspecific. We
aimed to develop and externally validate a risk prediction model using concentration of vagi-
nal fluid fetal fibronectin (quantitative fFN), in combination with clinical risk factors, for the
prediction of spontaneous preterm birth and assessed its cost-effectiveness.
Methods and findings
Pregnant women included in the analyses were 22+0 to 34+6 weeks gestation with signs and
symptoms of preterm labour. The primary outcome was spontaneous preterm birth within 7
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days of quantitative fFN test. The risk prediction model was developed and internally vali-
dated in an individual participant data (IPD) meta-analysis of 5 European prospective cohort
studies (2009 to 2016; 1,783 women; mean age 29.7 years; median BMI 24.8 kg/m2; 67.6%
White; 11.7% smokers; 51.8% nulliparous; 10.4% with multiple pregnancy; 139 [7AU : PleasenotethatspacesinnumbershavebeenchangedtoperiodstoindicatedecimalpointsinthemaintextandinTables1   3:Pleaseconfirmthatthischangeisvalid:.8%] with
spontaneous preterm birth within 7 days). The model was then externally validated in a pro-
spective cohort study in 26 United Kingdom centres (2016 to 2018; 2,924 women; mean
age 28.2 years; median BMI 25.4 kg/m2; 88.2% White; 21% smokers; 35.2% nulliparous;
3.5% with multiple pregnancy; 85 [2.9%] with spontaneous preterm birth within 7 days). The
developed risk prediction model for spontaneous preterm birth within 7 days included quanti-
tative fFN, current smoking, not White ethnicity, nulliparity, and multiple pregnancy. After
internal validation, the optimism adjusted area under the curve was 0.89 (95% CI 0.86 to
0.92), and the optimism adjusted Nagelkerke R2 was 35% (95% CI 33% to 37%). On exter-
nal validation in the prospective UK cohort population, the area under the curve was 0.89
(95% CI 0.84 to 0.94), and Nagelkerke R2 of 36% (95% CI: 34% to 38%). Recalibration of
the model’s intercept was required to ensure overall calibration-in-the-large. A calibration
curve suggested close agreement between predicted and observed risks in the range of pre-
dictions 0% to 10%, but some miscalibration (underprediction) at higher risks (slope 1.24
(95% CI 1.23 to 1.26)). Despite any miscalibration, the net benefit of the model was higher
than “treat all” or “treat none” strategies for thresholds up to about 15% risk. The economic
analysis found the prognostic model was cost effective, compared to using qualitative fFN,
at a threshold for hospital admission and treatment of�2% risk of preterm birth within 7
days. Study limitations include the limited number of participants who are not White and lev-
els of missing data for certain variables in the development dataset.
Conclusions
In this study, we found that a risk prediction model including vaginal fFN concentration and
clinical risk factors showed promising performance in the prediction of spontaneous preterm
birth within 7 days of test and has potential to inform management decisions for women with
threatened preterm labour. Further evaluation of the risk prediction model in clinical practice
is required to determine whether the risk prediction model improves clinical outcomes if
used in practice.
Trial registration
The study was approved by the West of Scotland Research Ethics Committee (16/WS/
0068). The study was registered with ISRCTN Registry (ISRCTN 41598423) and NIHR
Portfolio (CPMS: 31277).
Author summary
Why was this study done?
• Preterm labour is notoriously challenging for clinicians to diagnose due to the nonspe-
cific nature of presenting signs and symptoms.
PLOS MEDICINE A risk prediction model for preterm birth
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003686 July 6, 2021 2 / 22
Datashare). The DOI for data availability is https://
datashare.ed.ac.uk/handle/10283/3885.
Funding: This publication presents independent
research funded by the National Institute for Health
Research (NIHR) HTA Programme (Project
Number 14/32/01). All listed authors were funded
via this programme. Funder website URL: https://
www.nihr.ac.uk/explore-nihr/funding-programmes/
health-technology-assessment.htm. The funder
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. SJS is funded by the Wellcome Trust
(209560/Z/17/Z). The funder had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript. We are
grateful to HOLOGIC (Marlborough, MA, USA) for
providing adapted analyzers at each site allowing
quantitative fFN values to be masked from
clinicians and offered training and support to each
site for fFN testing. They also allowed QUIDS sites
to purchase tests at the lowest list price (NHS
treatment cost). HOLOGIC had no involvement in
data collection, analysis or interpretation, and no
role in the writing of this manuscript or the
decision to submit for publication. We are also
grateful to PARSAGEN DIAGNOSTICS who gifted
Partosure test kits for a substudy comparing
different biochemical test of preterm labour (to be
reported separately) and offered training and
support to sites and MEDIX BIOCHEMICA who
provided test kits at a reduced cost and offered
training and support to sites. These companies had
no other involvement in study design,
implementation, analysis or interpretation of
results.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: SJS is a member of
PLOS Medicine’s Editorial Board. All authors had
financial support from National Institute for Health
Research (NIHR) National Institute for Healthcare
Research; SJS reports financial support form the
Wellcome Trust (209560/Z/17/Z), non-financial
support from HOLOGIC, non-financial support
from PARSAGEN, and non-financial support from
MEDIX BIOCHEMICA to support the conduct of the
study; JD reports grants from Nutrinia in 2017 and
2018 which were part of his salary to work as an
expert advisor on a trial; MC reports that she has
done advisory work for HOLOGIC unrelated to the
submitted work, and has been supported by
HOLOGIC to attend a conference in the last 12
months; ALD reports personal fees from HOLOGIC
outside the submitted work; and salary support
from the NIHR UCLH/UCL Biomedical Research
Centre; AK reports grants and prediction tests from
• The outcomes and health of preterm babies can be significantly improved by well-timed
and appropriate interventions, but unnecessary overtreatment of women is common
and costly.
• Qualitative fetal fibronectin (fFN) is one test used to aid the diagnosis of preterm
labour.
What did the researchers do and find?
• We developed and validated a risk prediction model to improve the prediction of
impending preterm birth using a combination of qualitative fFN results and additional
clinical risk factors.
• The primary outcome was spontaneous preterm birth within 7 days of fFN testing.
• We developed and internally validated the model using data from 1783 European
women and externally validated the model in a prospective cohort study of 2,924 UK
women. Women with signs and symptoms of preterm labour were included in the anal-
ysis between 22+0 to 34+6 weeks gestation.
• At a threshold of�2% risk of birth within 7 days of testing, we found the prognostic
model to be cost effective in comparison to fFN alone.
What do these findings mean?
• Our findings indicate that the prognostic model has promising potential to improve
prediction of spontaneous preterm birth.
• The model is well placed to aid management decisions and discussions with women pre-
senting with signs and symptoms of preterm labour.
• Limitations were that there were low numbers of participants in the studies who were
not White, and there were some missing data in the risk predictor development cohort.
IntroductionAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:
Preterm birth, defined as delivery before 37 completed weeks of gestation, is the leading cause
of neonatal morbidity and mortality, with nearly 15 million preterm births worldwide every
year [1,2]. The majority of preterm births result from spontaneous preterm labour [3]. Timely
interventions in women with preterm labour can substantially improve health outcomes for
preterm babies. Such measures include birth in a centre with appropriate neonatal care facili-
ties [4], antenatal corticosteroids for lung maturity administered within 7 days of birth [5], and
peripartum magnesium sulphate for neuroprotection [6]. However, establishing a diagnosis of
preterm labour is very challenging, as signs and symptoms of preterm labour are common and
can be nonspecific. Large numbers of women with symptoms of preterm labour are treated
unnecessarily in order to ensure appropriate treatment of the minority who actually give birth
preterm [7,8]. One-third of all antenatal hospital admissions are with a suspected diagnosis of
preterm labour [9], resulting in a substantial economic burden to health services [10] and
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negative financial and emotional impacts on women and families [11]. Unnecessary prophy-
lactic treatments cause adverse maternal and neonatal effects, for example, tocolytics can cause
adverse drug reactions in mothers, and unnecessary antenatal corticosteroids are associated
with adverse neurodevelopmental outcomes in children [12–14].
Clinical tests may help confirm or refute the diagnosis of preterm labour to help target
appropriate treatment. Transvaginal ultrasound measurement of cervical length is one strategy
that has moderate predictive performance, but it requires specialised equipment and highly
trained staff [15]. Biochemical tests of preterm labour measure the concentration of markers
of impending birth in cervicovaginal secretions, are easy to perform, and have potential for
widespread implementation, including in settings where ultrasound is unavailable. The most
established biochemical test is vaginal fluid fetal fibronectin (fFN; Hologic, Marlborough, Mas-
sachusetts, United States of America) [16]. This has moderate accuracy for ruling out impend-
ing preterm birth based on a single threshold of 50 ng/ml [10,16]. fFN concentration in ng/ml
(quantitative fFN) may have better prognostic value than a single threshold test [10]. However,
quantitative fFN does not have US Food and Drug Administration (FDA) Approval in the
USA, and recent United Kingdom National Institute of Healthcare Excellence (NICE) guid-
ance concluded that there was insufficient evidence to recommend use of quantitative fFN to
determine the risk of preterm labour [15].
Combining biochemical test results with clinical risk factors in a risk prediction model can
improve the predictive ability of a model [17]. We thus hypothesised that quantitative fFN
could be combined with information on other known risk factors for preterm birth to better
determine an individual’s risk of preterm birth and thereby help inform decision-making for
women with symptoms of preterm labour. We aimed to develop and externally validate a risk
prediction model for preterm birth comprising these 2 elements using robust methodology.
Methods
Study oversight
The QUIDS study (QUIDS: Quantitative fetal fibronectin to improve decision-making in
women with signs and symptoms of preterm birth) protocols were developed according to the
relevant guidelines [17–19], published [20,21], and made available through the ISRCTN and
study websites. The individual participant data (IPD) meta-analysis was registered on the
International Prospective Register of Systematic Reviews (PROSPERO; CRD42015027590),
and the main prospective cohort study (ISRCTN 41598423) was registered. The research was
approved by the West of Scotland Research Ethics Committee (16/WS/0068). All participants
gave written informed consent.
The findings are reported in line with the Transparent Reporting of a multivariable predic-
tion model for Individual Prognosis or Diagnosis (TRIPOD) statement (S1 Table) [22].
Choice of health technology
The choice to include quantitative fFN was based on it being the only quantitative biochemical
test of preterm labour available, and previous research had concluded it may have potential to
be a more useful predictor of preterm birth than when used as a dichotomous test [10]. Two
other biochemical tests of preterm labour are also marketed in some countries—Actim Partus
(Medix Biochemica, Espoo, Finland), which measures phosphorylated insulin-like growth fac-
tor binding protein-1 (phIGFBP-1), and Partosure (Parsagen Diagnostics, Boston, Massachu-
setts, USA), which measures placental alpha microglobulin-1 (PAMG-1); but evidence
supporting their use is currently limited [15]. We performed an exploratory substudy compar-
ing test performance that will be published separately.
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Model outcome, target population, and candidate predictors
We included in the analyses pregnant women who were 22+0 to 34+6 weeks gestation with signs
and symptoms of preterm labour (as defined by investigators), intact membranes, and no con-
traindication to fFN testing (Table A in S1 Text). The primary outcome was spontaneous pre-
term birth within 7 days of quantitative fFN test, which was a binary outcome. The choice of
this outcome was determined by our previous qualitative study of women and clinicians [23].
We prespecified candidate predictors (i.e., those, considered to have potential to influence
the risk of spontaneous preterm birth before model development). These are shown in Table B
in S1 Text. Only maternal age, BMI, ethnicity, smoking, nulliparity, multiple pregnancy, gesta-
tional age at assessment, previous spontaneous preterm birth before 34 weeks, cervical length,
and fFN were available in each study, and, therefore, we included these 10 candidate predictors
in the model development. All included candidate predictors are available around the time of
initial assessment for signs and symptoms of preterm birth. Tocolysis was included in sensitiv-
ity analysis to explore any potential treatment effect on delaying birth.
Predictive performance measures
After model development, we examined the predictive performance of the model’s predicted
risks both internally (using the development data) and externally (using new data), in terms of
discrimination and calibration. We summarised the discrimination performance using the
area under the receiver operating characteristic curve (AUC) (with 0.5 representing no dis-
crimination beyond chance and 1 perfect discrimination). We visualised calibration of pre-
dicted and observed risks using a calibration plot including a nonparametric (loess smoother)
calibration curve and the ratio of predicted (expected) to observed risk for each 10th of pre-
dicted risk. We quantified calibration across all participants by the calibration slope (ideal
value 1), calibration-in-the-large (ideal value 0), and expected to observed ratio (ideal value 1).
We expressed overall model fit using Nagelkerke R2.
Model development
The IPD meta-analysis included prospective cohort studies or randomised control trials of women
with signs and symptoms of preterm labour that included quantitative fFN results determined by
10Q rapid fFN analyser system and pregnancy outcome data. Methods to identify studies are
described in the published protocol [21]. In brief, prior to applying for funding for the study (April
2014), we performed a literature search for completed and ongoing cohort studies of quantitative
fFN using search terms for quantitative fFN and preterm birth, including databases, clinical trial
registries, general search engines, and systematic reviews, and consulted preterm birth researchers
and networks and the manufacturers of quantitative fFN (Hologic) to help ensure capture of all rel-
evant studies. Study manuscripts and/or protocols were screened by 2 researchers. We identified
10 studies of quantitative fFN that were potentially eligible. Four early datasets (in 3 manuscripts)
used ELISA to determine the concentration of fFN and were excluded as the different method of
analysis and earlier period of study would increase heterogeneity [24,25,26]. Therefore, 6 studies
fulfilled the eligibility criteria, of which 5 could provide data. Details and assessment of bias of
included studies are in Table C in S1 Text and Table D in S1 Text.
Data were cleaned prior to analysis. Multiple imputation of missing values by chained equa-
tions was performed within each original study separately [27]. Sixty imputations were per-
formed, and Rubin’s rules used to combine estimates across datasets.
We assessed heterogeneity of predictor effects across the studies providing IPD using a
2-stage approach, fitting a model with all candidate predictors in each participating study, and
then performing a random-effects meta-analysis of each predictor’s adjusted effect. We
PLOS MEDICINE A risk prediction model for preterm birth
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quantified heterogeneity of the predictor effects using estimated between-study variance (τ2)
and I2 (Table E in S1 Text).
We used logistic regression to develop models. Our intention was to include predictors that
were available in each study (Table B in S1 Text.) and that had low heterogeneity of their
adjusted effect across studies. Although cervical length was included in all studies, there were
high levels (85%) of missing data in 2 of the studies. This reflects the fact that cervical length
measurement in women with symptoms of preterm labour requires 24-hour availability of
highly skilled staff and ultrasound equipment and is not universally available. We therefore
excluded cervical length from our initial model but included it in an alternative model (with
data from the 3 studies with near-complete observations on cervical length) to explore whether
it had potential to improve discrimination of the quantitative fFN-based risk prediction
model. We used a one-stage IPD meta-analysis framework with separate intercept term per
study to account for clustering. We used backwards selection based on an Akaike’s informa-
tion criterion and a p-value of<0�15 (also a full model was considered; see later). Continuous
predictors were analysed on their continuous scale. Nonlinear terms were identified using
multivariable fractional polynomials. Apparent model performance was assessed in the same
data used for model development.
Internal validation
We performed internal validation using nonparametric bootstrap resampling with 100 boot-
strap samples (replicating all steps of our model development), in particular to estimate opti-
mism due to overfitting. For each performance measure, the differences between the bootstrap
model’s apparent value in each bootstrap sample and its test value in the original dataset were
averaged to give the estimated optimism. We then subtracted this optimism from apparent
performance estimates of the original model to give optimism-adjusted estimates. We used the
optimism-adjusted calibration slope as a uniform shrinkage factor to shrink the beta coeffi-
cients of the original model to adjust for overfitting. Subsequently, we reestimated study-spe-
cific intercept terms while fixing the shrunken beta coefficients (via an offset term) to ensure
that overall calibration-in-the-large was maintained in each study separately.
External validation
We performed a prospective cohort study of women in 26 consultant-led obstetric units in the
UK between June 2016 and October 2018 to externally validate the developed risk prediction
model, in accordance with a published protocol [20]. Hospitals had different levels of neonatal
care facilities in both rural and urban settings (Table F in S1 Text).
Women with signs and symptoms of preterm labour (any or all of back pain, abdominal
cramping, abdominal pain, light vaginal bleeding, vaginal pressure, uterine tightenings or con-
tractions), in whom admission/treatment were being considered, were identified on presentation
to obstetric services. Informed consent was invited before speculum examination. This approach
meant that vaginal fluid fFN samples were collected at routine speculum examination, as they
are in clinical practice. However, certain exclusion criteria could only be applied at speculum
examination (for example, vaginal bleeding or evidence of ruptured membranes), so a propor-
tion of women were not eligible for fFN testing after consent was given. These data are reported
but not included in analysis. Further details of cost-effectiveness and acceptability of the model
and experiences of clinicians and women involved in the study will be reported elsewhere.
Samples for fFN analysis were taken with an fFN specimen collection kit as per manufactur-
er’s instructions. The sample was run at a near bedside Rapid fFN 10Q analyser specially
adapted for the study. The quantitative fFN result was masked from clinicians and stored as a
PLOS MEDICINE A risk prediction model for preterm birth
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3-letter code. The qualitative fFN result (positive/negative/invalid based on a 50-ng/ml thresh-
old) was displayed for clinicians to base clinical decision-making on, according to local
protocols.
Samples were run as per manufacturer’s instructions (Table G in S1 Text) with appropriate
quality control measures (Table H in S1 Text). Screening data and data about quantitative fFN
testing were collected on paper-based case report forms, which were then inputted onto a web-
based electronic database by research staff. All other data were collected from the participant
records and recorded on the study database.
The study database was locked on 14 January 2019. Data were cleaned, and multiple impu-
tation of missing data performed as described above (using 8 imputations). A random-effects
meta-analysis was used to combine the 5 study-specific intercepts included in the developed
prediction model, and the pooled estimate was then used as the intercept when applying the
model to individuals in the prospective cohort data. Measures of the model’s performance
were then assessed using similar methodology to that described above. Performance was also
examined after recalibration-in-the-large, which uses the external validation data to update the
original model’s intercept while holding predictor effects at their original value.
Additional models and subgroup analyses
During model development in the IPD meta-analysis, we also examined the inclusion of all
predictors within the model (i.e., without variable selection; this was not prespecified) and
explored the inclusion of cervical length (as described above inModel Development). A further
investigation included a model with tocolysis as a categorical variable (administered/not
administered) to explore any potential treatment effect of tocolysis in delaying birth (results
shown in Table I in S1 Text).
Additional analyses that were not prespecified were undertaken in the external validation
cohort to test the robustness of our model and included validating the model (i) with an outcome
of all preterm births within 7 days (i.e., including spontaneous and provider initiated preterm
births, as opposed to only spontaneous preterm births); (ii) in singletons only (as opposed to
including twins); and (iii) in a complete-case analysis (as opposed to one with imputation of miss-
ing data). We had intended to do a further analysis with all fFN test results included (as opposed
to including only the first recorded fFN result of each study participant); however, the number of
women who had more than one fFN test was too low to make this robust (206; 7.0%).
Net benefit
In order to evaluate the potential clinical value of using the risk prediction model to inform
decision-making, we performed net benefit analyses (which was not prespecified), where bene-
fits and harms of a risk prediction model are put on the same scale to allow direct comparison
[28]. We plotted the standardised net benefit across a range of predicted risks of preterm birth
within 7 days (0% to 20%). For the purpose of this analysis, we assumed that the standard of
care for this population with signs and symptoms of preterm labour was to “treat” (e.g., admit
to an appropriate hospital, give antenatal corticosteroids and magnesium sulphate) and that a
percentage predicted risk of preterm birth would be used for “ruling out” treatment.
Sample size calculations
The sample size for model development was fixed by the number of women participating in
the existing 5 studies (1,783 women; 139 events); the number of predictors relative to the num-
ber of events was about 14, and the data met minimum sample size criteria for model develop-
ment [29]. For external validation, our initial sample size calculation at the cohort study outset
PLOS MEDICINE A risk prediction model for preterm birth
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(1,602) was based on an anticipated event proportion of between 6% and 12%. However, it
quickly became apparent that our event proportion was lower than estimated (stabilising at
around 3%). Further, guidance emerged recommending that a minimum of around 100 events
and 100 nonevents were needed for risk prediction model validation [30]. We therefore revised
our sample size calculation during the study, aiming for 3,000 participants, to obtain approxi-
mately 100 events of preterm birth within 7 days of testing.
Cost-effectiveness analysis
We undertook an economic evaluation from the perspective of the UK National Health Service
(NHS) and Prescribed Specialised Services. The analysis was undertaken for cost year 2017/
2018 and was conducted according to best practice guidelines [31,32]. The mean resource use
for each participant was estimated using data from the prospective cohort study and reference
unit costs (Table J in S1 Text). We performed multivariable analysis of the difference in arith-
metic mean of the cost [33], estimating a number of generalised linear models with different
families and link functions. The choice of final model was based on goodness of fit using the
modified Park test. We calculated the percentage (0% to 100%) probability of spontaneous pre-
term birth with 7 days for each participant in the cohort study using the externally validated
QUIDS risk prediction model. Qualitative fFN results were categorised as positive (high risk)
or negative (low risk) based on a single threshold of 50 ng/ml. Table K in S1 Text provides all
model parameters used in the cost-effectiveness analysis.
The base case cost-effectiveness analysis compared the cohort study results for the QUIDS
risk prediction model versus a treat-all approach (recommended by NICE at gestations of less
than 30 weeks gestation [16]) and versus use of qualitative fFN alone (the most commonly
used test of preterm labour in the UK [34], recommended by NICE as an option for women
with signs and symptoms of preterm labour over 30 weeks gestation [16]), reporting the incre-
mental cost per correct prognosis, incremental cost per quality-adjusted life days (QALDs)
gained and incremental net monetary benefit (NMB), using a willingness to pay per QALD of
£54.79, equivalent to the UK threshold £20,000 per quality-adjusted life year (QALY).
The decision model was based on a decision tree framework (Fig A in S1 Text). In order to
capture the longer-term cost and health outcomes associated with infants who did and did not
receive treatment, we extrapolated the 7-day outcomes over a lifetime horizon. For the lifetime
horizon, QALYs, rather than QALDs, are presented. Key assumptions for the models are
detailed in Table L in S1 Text.
Software
Data were cleaned in SPSS version 24. All statistical analyses were performed in R (version
3.6.1). All cost-effectiveness analyses were performed using STATA (version 19).
Results
Model development and internal validation
We meta-analysed the IPD from 5 clinical studies of quantitative fFN to create a risk predic-
tion model for spontaneous preterm birth within 7 days of fFN test [20,21]. Details of the IPD
meta-analysis cohort are shown in Table 1 (characteristics after multiple imputation of missing
data are shown in Table M in S1 Text). The IPD contained a total of 1,783 women with signs
and symptoms of preterm labour recruited in the 5 studies between 2009 and 2016, of which
139 women had spontaneous preterm birth (7.8%) within 7 days of fFN test.
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We included 10 prespecified candidate predictors with potential to influence the risk of
spontaneous preterm birth in the model (Table B in S1 Text) [20,21]. After backwards selec-
tion, predictors that remained in the QUIDS risk prediction model were quantitative fFN,
smoking, ethnicity, nulliparity, and multiple pregnancy (Table 2). Of note, gestational age did
not influence the probability of spontaneous preterm birth within 7 days (Table N in S1 Text).
Quantitative fFN was transformed (square root) because of nonlinearity. The apparent dis-
crimination performance of the model was AUC of 0.89 (95% CI 0.86 to 0.92), with Nagelk-
erke R2 being 36% (95% CI 34% to 37%). Nonparametric bootstrap resampling resulted in a
uniform shrinkage factor of 0.94, which was applied to the model’s predicted effects to adjust
for this small overfitting. The optimism adjusted AUC was 0.89 (95% CI 0.86 to 0.92), and the
optimism-adjusted Nagelkerke R2 was 35% (95% CI 33% to 37%).
We compared the performance of the developed model to that of a model including all
potential predictors (i.e., without variable selection) and a model with variable selection that
included cervical length (which requires specialised staff and equipment to perform). The dis-
crimination of these additional models was similar to the principal model developed, with
model performance after internal validation showing small improvement in AUCs of 0.90
(95% CI 0.88 to 0.93) and 0.92 (95% CI 0.89 to 0.94), respectively (full models shown in Table I
in S1 Text), and net benefit analyses showed the models with and without cervical length to
have very similar potential utility (Fig B in S1 Text). We therefore chose the original and most
parsimonious model (the one with fewest predictors, which we call the QUIDS risk prediction
model) for further validation.
External validation
We performed a prospective cohort study of women in 26 consultant-led obstetric units in the
UK between June 2016 and October 2018, for external validation of the QUIDS model [20].
The study flowchart (Fig 1) shows that 27 of 2,968 (0.91%) participants were ineligible at specu-
lum examination or unable to have fFN testing completed. In addition, 17 of 2,941 (0.58%) fFN
tests had an invalid result. AAU : PerPLOSstyle; numeralsarenotallowedatthebeginningofasentence:Therefore; pleaseconfirmthattheeditstothesentenceAtotalof 2; 924womenwereincludedinthefinal:::arecorrect; andamendifnecessary:total of 2,924 women were included in the final analysis dataset.
The baseline characteristics of participants are shown in Table 1 (characteristics after impu-
tation are in Table M in S1 Text). There were 85 events of spontaneous preterm birth within 7
days of fFN test in 2,924 women (2.9%).
On external validation of the QUIDS model (Table 3), the AUC remained as 0.89 (0.84 to
0.94), and Nagelkerke R2 was 36% (95% CI 34% to 38%). Calibration-in-the-large was 0.26
(95% CI 0.25 to 0.28), and so we updated the intercept of the QUIDS model by recalibrating
the intercept to ensure perfect calibration-in-the-large for this UK population (Predicted risk
[Expected risk or “E”]/Observed cases [“O”] = 1) (Fig 2). Subsequently, the calibration curve
suggested close agreement between predicted and observed risks in the range of predictions
0% to 10% (Fig 2), but some miscalibration (underprediction) at higher risks (slope 1.24 (95%
CI 1.23 to 1.26)).
Model performance was similar across a number of additional analyses (Table P in S1 Text)
validating the model (i) with an outcome of all preterm births within 7 days (i.e., including
spontaneous and medically indicated preterm births, as opposed to only spontaneous preterm
births); (ii) in singletons only (as opposed to including twins); and (iii) in a complete-case
analysis (as opposed to one with imputation of missing data).
Net benefit
In order to evaluate the potential clinical value of the risk prediction model to inform deci-
sion-making, we performed net benefit analyses, where benefits and harms of a risk prediction
PLOS MEDICINE A risk prediction model for preterm birth
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Table 1. Baseline characteristics of the QUIDS IPD meta-analysis dataset and QUIDS prospective cohort.
Individual participant meta-analysis dataset (model development) n = 1,783 Prospective cohort (external












n = 528 n = 455 n = 452 n = 86 n = 262 n = 1,783
Age (mean [SD] years) 29.4 (5.3) 29.5 (5.2) 29.5 (6.0) 30.0 (6.1) 31.0 (6.1) 29.7 (5.6) 28.2 (5.7)
Missing n (%) - - - - - - 31 (1.1)
BMI (median [IQR] kg/m2) 25.6 (23.5–28.1) 25.7 (23.1–
28.7)








Missing n (%) 303 (57.4) 202 (44.4) 2 (0.4) 0 22 (8.4) 529 (29.7) 51 (1.7)
Ethnicity
White 342 (64.8) 352 (77.4) 226 (50.0) 58 (67.4) 145 (55.3) 1,123
(63.0)
2,544 (87.0)
South Asian 8 (1.5) 4 (0.9) 25 (5.5) 6 (7.0) 30 (11.5) 73 (4.1) 165 (5.6)
East Asian 6 (1.1) 12 (2.6) 10 (2.2) 3 (3.5) 12 (4.6) 43 (2.4) 7 (0.2)
African, Caribbean, Middle
East
63 (11.9) 69 (15.2) 159 (35.2) 15 (17.4) 57 (21.8) 363 (20.4) 98 (3.4)
Other 23 (4.3) 6 (1.3) 32 (7.1) 4 (4.7) 2 (0.8) 67 (3.8) 68 (2.3)
Missing n (%) 86 (16.3) 12 (2.6) 0.0 0.0 16 (6.1) 114 (6.4) 42 (1.4)
Currently smoking n (%) 71 (13.4) 41 (9.0) 58 (12.8) 11 (12.8) 9 (3.4) 190 (10.7) 608 (20.8)
Missing n (%) 43 (8.1) 42 (9.2) 3 (0.7) 0.0 21 (8.0) 109 (6.1) 40 (1.4)
Nulliparity n (%) 288 (54.5) 262 (57.6) 200 (44.2) 34 (39.5) 140 (53.4) 924 (51.8) 951 (32.5)
Missing n (%) - - - - - - 171 (5.8)
Multiple pregnancy n (%) 85 (16.1) 67 (14.7) 20 (4.4) 0 (0) 14 (5.3) 186 (10.4) 99 (3.4)
Missing n (%) - - - - - - 29 (1.0)
Gestational age (median [IQR]
weeks)
29.4 (26.8–31.3) 29.6 (26.7–
31.6)








Missing n (%) 10 (0.3)
Previous spontaneous preterm
birth <34 weeks n (%)
69 (13.1) 39 (8.6) 68 (15.0) 7 (8.1) 13 (5.0) 196 (11.0) 121 (4.1)
Missing n (%) - - - - - - 179 (6.1)
Cervical length (mean [SD]
mm)
25.0 (12.3) 21.3 (9.5) 26.9 (14.0) 29.8 (9.0) 14.2 (7.0) 23.8 (11.5)
Missing n (%) 0.0 0.0 343 (75.9) 0.0 224 (85.5) 567 (31.8)
Qualitative fFN positive n (%) 199 (37.7) 197 (43.3) 105 (23.2) 12 (14.0) 35 (13.4) 548 (30.7) 413 (14.1)
Missing n (%) 1 (<0.1)
Quantitative fFN (median
[IQR] ng/ml)
17.0 (4.0–112.5) 34 (8.0–217) 7.0 (3.0–43.8) 4.0 (2.0–11.3) 4.0 (2.0–16.3) 11.0 (3.0–
79.0)
7 (4–22)
Missing n (%) 2 (<0.1)
Tocolysis n (%) 345 (65.3) 319 (70.1) 36 (8) 7 (8) 10 (3.8) 717 (40.2) 165 (5.6)
Missing n (%) 78 (2�7)
Outcome
Spontaneous preterm birth <7
days n (%)
70 (13.3) 48 (10.5) 14 (3.1) 2 (2.3) 5 (1.9) 139 (7.8) 85 (2.9)
Baseline characteristics of participants in QUIDS IPD meta-analysis datasets and participants in the QUIDS prospective cohort study.
fFN, fetal fibronectin; IPD, individual participant data; IQR, interquartile range; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003686.t001
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model are put on the same scale to allow direct comparison [28]. Fig 3 shows the net benefit
analysis of the QUIDS model (after recalibration of the intercept) compared to strategies of
treat all (default) and treat none; the potential benefit (from reducing unnecessary treatment)
and potential harms (from “missing” a case of preterm birth) are plotted on the same scale to
allow direct comparison across a range of risk predictions. Alternative approaches of “Treating
all” and “Treating none” are included for comparison. The QUIDS model is better than a
treat-all approach at predicted risks of less than around 15%. The components of the receiver
operator characteristic curve (sensitivity and 1-specificity) at different thresholds of risks are
presented in Fig C in S1 Text. Using a risk threshold of 2% to define high risk, the model has
sensitivity of 0.85 (95% CI 0.76 to 0.93) and specificity of 0.28 (95% CI 0.27 to 0.30).
Table 2. QUIDS risk prediction model for the prediction of spontaneous preterm birth within 7 days of quantita-
tive fFN test developed (A) and internally validated (B) by IPD meta-analysis.
Original model Optimism-adjusted model
Study 1 intercept (95% CI) [35] −4.828 (−6.435–−3.221) −4.556 (−6.164–−2.949)
Study 2 intercept (95% CI) [36] −5.524 (−7.131–−3.917) −5.213 (−6.820–−3.606)
Study 3 intercept (95% CI) [37] −5.937 (−7.628–−4.246) −5.603 (−7.295–−3.912)
Study 4 intercept (95% CI) (QFCAPS) −5.692 (−7.819–−3.565) −5.372 (−7.498–−3.245)
Study 5 intercept (95% CI) (UCLH/Whit) −6.149 (−8.046–−4.252) −5.803 (−7.700–−3.906)
Meta-analysed intercept −5.263 (−6.046–−4.479)
qfFN
Beta coefficient 2.029 1.915
OR (95% CI) 7.61 (5.68–10.19) 6.79 (5.07–9.09)
Smoking
Beta coefficient −0.728 −0.687
OR (95% CI) 0.48 (0.23–1.03) 0.50 (0.24–1.07)
Not White ethnicity
Beta coefficient −0.147 −0.139
OR (95% CI) 0.86 (0.50–1.48) 0.87 (0.51–1.49)
Nulliparity
Beta coefficient 0.391 0.370
OR (95% CI) 1.48 (0.95–2.30) 1.45 (0.93–2.25)
Multiple pregnancy
Beta coefficient 0.884 0.834
OR (95% CI) 2.42 (1.42–4.11) 2.30 (1.36–3.91)
Model performance
Nagelkerke R2 36% (34%–37%) 35% (33%–37%)
AUC 0.89 (0.86–0.92) 0.89 (0.86–0.92)
The QUIDS risk prediction model for the prediction of spontaneous preterm birth within 7 days of quantitative fFN
test in women with signs and symptoms of preterm labour. Column A shows the baseline model and column B the
model after internal validation and adjustment for optimism.
AUC, area under the curve; CI, confidence interval; E/O, expected/observed; fFN, fetal fibronectin; IPD, individual
participant data; OR, odds ratio; qfFN, quantitative fetal fibronectin ((qfFN+1)/100)^0.5).
Apparent model performance (A) is summarised using the means from the pooled imputed datasets for simplicity.
https://doi.org/10.1371/journal.pmed.1003686.t002
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QUIDS risk prediction model
The externally validated QUIDS risk prediction model with intercept recalibrated for the pro-
spective UK cohort population has the equation:
Log odds of spontaneous preterm birth within 7 days of fFN test ¼
1:915�ððqfFN þ 1=100Þ
0:5
Þ þ 0:370�ðNulliparousÞ þ 0:834�ðMultiple pregnancyÞ 
0:687�ðCurrent smokerÞ   0:139�ðNot White ethnicityÞ   5:002;
where qfFN is the concentration of quantitative fFN in ng/ml, and Nulliparous, Multiple preg-
nancy, Current smoker, and Not White ethnicity are binary variables with a value of 0 or 1
Fig 1. Flowchart of participants in the QUIDS prospective cohort study. Flowchart showing participants in the QUIDS prospective cohort study. fFN, fetal fibronectin;
qfFN, quantitative fetal fibronectin.
https://doi.org/10.1371/journal.pmed.1003686.g001
Table 3. Performance of QUIDS risk prediction model for the prediction of spontaneous preterm birth within 7
days of quantitative fFN test in external validation cohort.
A. Applying QUIDS model using pooled intercept from
model development studies
B. Applying QUIDS model using updated intercept
(recalibrated to UK population)




Nagelkerke R2 36% (34%–38%) 36% (33%–37%)
AUC 0.89 (0.84–0.94) 0.89 (0.84–0.94)




Calibration slope 1.24 (1.23–1.26) 1.24 (1.23–1.26)
Performance is shown when the intercept is derived from meta-analysis of the individual intercepts of the 5
contributing studies used for model development (A) and after recalibration updating the model intercept estimated
using the external validation cohort (B).
AUCAU : AnabbreviationlisthasbeencompiledforthoseusedinTable3:Pleaseverifythatallentriesarecorrect:, area under th rece ver : operating characteristic curve; fFN, fetal fibronectin.
https://doi.org/10.1371/journal.pmed.1003686.t003
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dependent on clinical risk factors. We present this as a risk prediction calculator that is avail-
able at https://argoshare.is.ed.ac.uk/connect/#/apps/340/access.
Cost-effectiveness
Resource use and cost estimates from QUIDS prospective cohort study (Table Q in in S1 Text)
were used in the final health economic model. The cost-effectiveness results comparing the
QUIDS risk prediction model to a treat-all scenario and qualitative fFN are detailed in Table R
in S1 Text (7-day time horizon) and Table S in S1 Text (lifetime horizon).
Compared with a treat-all strategy, the risk prediction model at�2% risk is associated with
a reduction in QALDs of 0.0005 and a cost reduction of £866 over a 7-day horizon (incremen-
tal cost-effectiveness ratio [ICER]: £1,732,000, NMB: £856). Over a lifetime horizon, the risk
prediction model at�2% risk is associated with a reduction in QALYs of 0.0006 and a cost
reduction of £840 (ICER: £1,400,000, NMB: £827).
Compared to qualitative fFN alone, the risk prediction model increases costs by £41 per
patient with a QALD gain of 0.002 over a 7-day horizon (ICER: £20,500, NMB: £-1). Over a
lifetime horizon, the risk prediction model at�2% risk is associated with a QALY gain of
Fig 2. Calibration plot of predicted versus observed risk for the QUIDS model validation in the prospective cohort data. Calibration plot with predicted versus
actual risk the QUIDS logistic regression model as applied to the prospective cohort study data (after multiple imputation; multiple imputation set 1 used to generate
plot after recalibration with updated intercept). Data relating to grouped observations are shown in Table O in S1 Text. CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003686.g002
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0.008 and an additional cost of £40 per patient (ICER: £5,000, NMB: £120). This is highly cost
effective given the recommended NICE threshold of £20,000/QALY.
Discussion
We have developed a model for risk prediction of preterm birth within 7 days of fFN test in
women with signs and symptoms of preterm labour, based on the quantitative fFN test and
clinical risk factors. The model shows promising performance when externally validated and
recalibrated in a UK population, with potential net benefit when used to inform clinical deci-
sion-making, and is cost effective.
Current NICE guidance suggests that at gestations of 30 weeks or less, a treat-all strategy for
women with signs and symptom of preterm labour is more cost effective than a strategy using
tests of preterm labour [16]. Our cost-effectiveness analysis, based on prospectively collected
data, found that the QUIDS risk prediction model at a risk prediction threshold of 2% was
Fig 3. Net benefit analysis of QUIDS risk prediction model. Net benefit analysis (and 95% confidence intervals). The figure shows the standardised net benefit (to
visualise the potential benefit from reducing unnecessary treatment, and potential harms from “missing” a case of preterm birth plotted on the same scale) at different %
probabilities (from 0%–20%) of spontaneous preterm birth within 7 days as predicted by the QUIDS risk prediction model (blue lines) after recalibration of the intercept,
compared to a policy of treating all women with symptoms (black dashed line) and a policy of treating no women (black horizontal line). Standardised net benefit was






FNR rð Þ=p, where sNB is defined by true negative rate (TNR), the false negative rate (FNR), the
prevalence of preterm birth within 7 days (p), and the risk threshold (r) odds of low-risk designation at the % risk prediction [38]. FNRAU : AnabbreviationlisthasbeencompiledforthoseusedinFig3:Pleaseverifythatallentriesarecorrect:, false negativ r te; sNB,
standardised net benefit; TNR, true negative rate.
https://doi.org/10.1371/journal.pmed.1003686.g003
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likely to be cost effective compared to alternative strategies of treat-all, or use of qualitative
fFN alone, across the range of gestations included in the study (22+0 to 34+6 weeks gestation).
Although the use of the QALY is limited in this context, we believe that a measure that
attempts to capture the morbidity impact of missed treatment (false negatives) is crucial. How-
ever, further research is required regarding the measurement of quality of life for infants and
how to appropriately value this.
Not all predictors in the QUIDS model performed as might have been predicted based on
prior clinical knowledge. For example, smoking and not being of White ethnicity are both rec-
ognised to be risk factors for spontaneous preterm birth overall, but in our model, they were
associated with a reduced risk of spontaneous preterm birth in women who present with
symptoms. The reasons for this are unclear, but it may reflect an interaction between risk fac-
tors and management decisions. For example, clinicians’ perception of smokers as being at
“high risk” of preterm birth may mean they perform an fFN test more readily in the presence
of minor symptoms in smokers than in nonsmokers. It should be noted that unexpected find-
ings are a recognised phenomenon in risk prediction models [39]. As the main aim of a predic-
tion model is to predict risk based on associations between predictors and the outcome,
associations should not be interpreted causally, and individual predictor effects are, in princi-
ple, not relevant. Nevertheless, model face validity is helped if predictor effects are as expected
[39], and further work will explore how best to present our risk prediction model and support-
ing information to clinicians to optimise confidence in the model.
Strengths of the study were size and methodological rigour, adhering to prespecified pub-
lished protocols and reporting guidelines, and inclusion of sensitivity analyses. A potential lim-
itation is the number of events in our external validation (85). We initially aimed to have at
least 100 births within 7 days of testing, but the event rate was lower than anticipated, and we
had a higher proportion of medically indicated preterm births than expected (prespecified as
being excluded from our main analysis). Nevertheless, confidence intervals for the discrimina-
tion, calibration, and net benefit performance were narrow. Furthermore, to our knowledge,
this is the largest published study of quantitative fFN, with more than 200 events included in
the development and validation analyses in total. Another potential limitation is the amount of
missing data for certain variables, for example, BMI in the development cohort. Multiple
imputation was used to address missing data, which has been shown to be a valid technique
for dealing with missing data within logistic regression models, resulting in less bias than
excluding all women with missing data [27]. The majority of study participants were White,
meaning that confidence intervals around risk estimates for women of other individual ethnic
groups were large. We therefore collapsed ethnicity groupings into White and not White in
our primary model. In future work, we would like to further refine risk estimates for women
of different ethnicities. The cost-effectiveness analysis was carried out from the perspective of
the UK NHS setting and may not be generalizable to other settings.
We believe that defining a single recommended risk prediction threshold to indicate treat-
ment is undesirable as the relative weight of harms and benefits of treatment (including hospi-
tal admission) are likely to vary across individuals and healthcare settings, and the perception
of benefits and harms are likely to be influenced by personal values and experience. We there-
fore propose that the QUIDS risk prediction model should be used to guide management deci-
sions in the context of the woman’s circumstances and preferences, as well as the healthcare
setting. Nevertheless, relatively conservative and narrow-range risk prediction thresholds are
indicated. In our prospective cohort study, the vast majority of preterm births within 7 days
occurred in the highest decile of risk, but this equated to a predicted risk estimate of only
around 20%. Furthermore, cost-effectiveness analysis supports use of a conservative risk
threshold of 2%, and net benefit supported anything up to 15%.
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Further evaluation of the risk prediction model in clinical practice is required to determine
whether the risk prediction model improves clinical outcomes if used in practice. We recali-
brated our model intercept to the UK population, as our original model was developed in an
international set of studies. Further evaluation of this revised intercept, and whether recalibra-
tion is needed in each local centre, would be worthwhile.
In conclusion, the QUIDS risk prediction model including vaginal fluid quantitative fFN
concentration and clinical risk factors showed promising performance in the prediction of
spontaneous preterm birth within 7 days of testing and can be considered for use as part of a
decision support tool to help guide management decisions for women with threatened preterm
labour. It is readily implementable, with potential for immediate benefit to women and babies
and health services, through avoidance of unnecessary admission and treatment.
Supporting information
S1 Table. Transparent Reporting of a multivariable prediction model for Individual Prog-
nosis or Diagnosis (TRIPOD) [22] Checklist.
(DOCX)
S1 Text. Table A. Details of inclusion and exclusion criteria for QUIDS study. QUIDS study
inclusion and exclusion criteria. fFN, fetal fibronectin; IPD, individual participant data; RCT,
randomised control trial. Table B. Prespecified candidate predictors for inclusion in the
QUIDS model and availability in each included study. Candidate predictors were prespecified,
based on their potential to influence risk of preterm birth, and included: fFN concentration
(ng/ml), previous spontaneous preterm birth, nulliparity (no previous pregnancy >24 weeks),
gestation at fFN test (weeks), maternal age (years), ethnicity, body mass index (BMI kg/m2),
smoking status, deprivation index, number of uterine contractions in set time period, cervical
dilatation (cm), vaginal bleeding, previous cervical treatment for cervical intraepithelial neo-
plasia, cervical length (measured by transvaginal cervical length, mm), singleton or multiple
pregnancy, and tocolysis. Only maternal age, BMI, ethnicity, smoking, nulliparity, multiple
pregnancy, gestational age at assessment, previous spontaneous preterm birth before 34 weeks,
cervical length, and fFN were available in each study, and, therefore, these 10 candidate predic-
tors were included in the model development. Tocolysis was included in sensitivity analysis to
explore any potential treatment effect on delaying birth. Table C. Details of eligible studies in
the IPD meta-analysis. Six studies fulfilled the eligibility criteria; at the time, only one study
was published (3), but three have subsequently been published (1, 2, 4). Five PIs agreed to pro-
vide data (Mol–Eufis; (2) van Baaren–Apostel-1; (1) Khalil–QFCAPS [Quantitative fetal fibro-
nectin, Cervical length and ActimPartus for the prediction of Preterm birth in Symptomatic
women]; unpublished, Shennan–EQUIPP [Evaluation of Fetal Fibronectin with a Quantitative
Instrument for the Prediction of Preterm Birth]; (3) David–UCLH/Whit [University College
London Hospital/Whittington], unpublished). The PI of the sixth study (STOP–Elovitz (4))
indicated data availability only after publication of the study, which occurred after completion
of our analysis. fFN, fetal fibronectin. Table D. Assessment of bias of studies included in the
IPD meta-analysis. Assessment of bias of studies included in the individual participant data
meta-analysis. Risk of bias checklist adapted from (5). Table E. Results two-stage random
effects meta-analysis for heterogeneity of predictor effects. Results of two-stage random effects
meta-analysis for heterogeneity of predictor effects individual participant meta-analysis. fFN,
fetal fibronectin. Table F. Sites for prospective cohort study. UK sites included in QUIDS pro-
spective cohort study. Table G. Description of fFN test and protocol for sampling. Description
of fetal fibronectin test and protocol for sampling. fFN, fetal fibronectin. Table H. Quality con-
trol measures for the Hologic Rapid fFN 10Q analyser. Description of quality control measures
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for the fetal fibronectin test. fFN, fetal fibronectin. Table I. Sensitivity analyses for model devel-
opment. Sensitivity analyses of different models developed using the IPD meta-analysis data-
set. Multivariable logistic analysis of all candidate predictors; selected candidate predictors
with cervical length (with data from the 3 studies with cervical length data completeness
>80%); tocolysis. qfFN = quantitative fetal fibronectin ((qfFN+1)/100)^0.5). Cervical length =
((cervical length+1)/10)^0.5). Table J. Resource use items and unit collected via case report
forms. Details of resource use items and unit collected via case report forms.
�
Hotel cost (58%
of total stay cost) applied. +Dosage based on British National Formulary recommended standard
dosage (mg). Unit cost is then estimated by multiplying dosage received in mg by unit cost per
mg. C, cost. CPAP, Continuous Positive Airway Pressure therapy; LNU, Local Neonatal Unit;
NICU, Neonatal Intensive Care Unit; SCBU, Special Care Baby Unit. Table K. Model parame-
ters used in the cost-effectiveness analysis. Analysis: The cost-effectiveness of alternative risk
prediction strategies was evaluated by its incremental cost-effectiveness ratio (ICER), which
was calculated according to: ICER = ΔCosts/ΔQALY, where ΔCosts is the difference in total
costs between risk prediction strategies, and ΔQALY is the difference in utility between risk
prediction strategies. This incremental cost-effectiveness ratio can be compared against a soci-
etal willingness-to-pay for QALY gains (£20,000 in line with NICE reference case for cost per
QALY. (15)) As considered QALYs a 7-day time horizon, we presented results in terms of cost
per quality-adjusted life day (QALD), assuming a willingness-to-pay for QALD gained of £55
per day. The cost-effectiveness of the risk prediction strategies could also be converted to the
NMB as there are multiple comparators. The NMB is a measure of the health benefit, expressed
in monetary terms, which incorporates the cost of the new strategy, the health gain obtained,
and the societal willingness to pay for health gains (£20,000). The NMB is expressed using the
following formula: NMB = (E�WTP)–C. Where E = effectiveness; WTP = willingness-to-pay
threshold; C = cost. The NMB approach is recommended when comparing more than one
intervention and provides a clear decision rule (i.e., if NMB > 0, the new strategy is cost effec-
tive). Results can also be presented incrementally as the incremental NMB. Table L. Key
assumptions for the cost-effectiveness models. Details of key assumptions made in the cost-
effectiveness models. QALY, quality-adjusted life year. Table M. Baseline characteristics of the
individual participant data meta-analysis dataset (A) and prospective cohort (B) study partici-
pants, derived from means of pooled imputations. Baseline characteristics of participants in
QUIDS individual participant data meta-analysis dataset (A) and prospective cohort (B) study
participants, derived from means of pooled imputations. fFN, fetal fibronectin; IQR, inter-
quartile range; SD, standard deviation. Table N. Probability of spontaneous preterm birth
within 7 days by gestational age in weeks. Table O. Data for calibration plot [Fig 2]. Mean
expected and observed (with 95% confidence interval [CI]) risk of spontaneous preterm birth
within 7 days for each of 10 risk groups (data for calibration plot [Fig 2]). Table P. Model per-
formance measures for prespecified sensitivity analyses of the QUIDS model. Model perfor-
mance measures for prespecified sensitivity analyses of the QUIDS model: Any preterm birth
(i.e., including provider initiated preterm births); singletons only and complete case analyses.
AUC, area under the curve. Table Q. Resource use and cost estimates from QUIDS prospective
cohort. Resource use and cost estimates from QUIDS prospective cohort. CPAP, Continuous
Positive Airway Pressure therapy; LNU, Local Neonatal Unit; NICU, Neonatal Intensive Care
Unit; SCBU, Special Care Baby Unit. Table R. Cost-effectiveness results comparing the QUIDS
risk predictor to a treat-all scenario and qualitative fFN (7-day time horizon). �ICER is in the
southwest quadrant in cost-effectiveness plane (cost saved per QALD lost). ICERs above
£20,000 are considered cost effective. QALD = Quality adjusted life days. ICER = Incremental
cost-effectiveness ratio. fFN, fetal fibronectin; NMB, net monetary benefit. Table S. Cost-effec-
tiveness results comparing the QUIDS risk predictor to a treat-all scenario and qualitative fFN
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(lifetime horizon) �ICER is in the southwest quadrant in cost-effectiveness plane (cost saved
per QALY lost). ICERs above £20,000 are considered cost-effective. fFN, fetal fibronectin;
ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; QALY, quality-
adjusted life years. Fig A. Decision tree framework. For each risk prediction strategy, the tree
initiates with the true prevalence of preterm labour. Those identified as “high risk” by the strat-
egy are admitted to a maternity unit with appropriate neonatal care facilities and receive ante-
natal corticosteroids. Those identified as “low risk” by the risk prediction strategy are not
admitted and do not receive antenatal corticosteroids. The model can also be run under a
hypothetical “treat all” strategy where all participants are admitted. The final destination in the
decision tree is 1 of 5 possible states for preterm births: stillborn, minor morbidity, major mor-
bidity, full health, and “did not give birth within 7 days.” Given this structure, the model
accounts for both the clinical and economic impact of false negative (low-risk result but gives
birth within 7 days) and false positive results (high-risk result but does not give birth within 7
days) from the risk prediction strategies. False negatives represent missed opportunities to treat
women with morbidity reducing antenatal corticosteroids, so infants born after a “false negative”
result have a greater probability of experiencing neonatal morbidity and mortality, incurring the
associated costs, quality of life, and survival impacts of these. False positives results will result in
women being admitted to hospital unnecessarily, incurring additional and unnecessary cost of
hospitalisation, interhospital transfer, and treatment. It is assumed that there are no quality of life
side effects for receiving unnecessary treatment. Fig B. Net benefit curves comparing the QUIDS
model with alternate models. The figure shows the standardised net benefit (to visualise the
potential benefit from reducing unnecessary treatment, and potential harms from “missing” a
case of preterm birth plotted on the same scale) at different % probabilities (from 0%–60%) of
spontaneous preterm birth within 7 days as predicted by (i) the QUIDS risk prediction model
including clinical risk factors and quantitative fetal fibronectin (fFN; blue line); compared to a
policy of treating all women with symptoms (dark grey line); an alternate model including clinical
risk factors and quantitative fFN + cervical length (red line); an alternate model including cervical
length alone (green dashed line); and a policy of treating no women (light grey horizontal line).







where standardised net benefit (sNB) is defined by true negative rate (TNR), the false negative
rate (FNR), the prevalence of preterm birth within 7 days (p), and the risk threshold (r) odds of
low-risk designation at the % risk prediction [16]. Fig C. Plot of receiver operator curve compo-
nents for QUIDS risk prediction model. Sensitivity (detection rate or true positive rate; black
line) and 1-specificity (false positive rate; blue dashed line) and 95% CI at different % probabilities
(between 0% and 10%) of spontaneous preterm birth within 7 days as predicted by the QUIDS
risk prediction model. For example, at a predicted risk of 2%, the model has sensitivity of 0.85
(95% CI 0.76 to 0.93) and false positive rate of 0.28 (95% CI 0.27 to 0.30). The cost benefit axis is
presented below the graph, with the cost indicating the ratio of “missed” cases (cost) to the num-
ber of cases where unnecessary treatment was avoided (benefit), at different levels of risk pre-
dicted by the QUIDS model.
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